We've updated our Privacy Policy to make it clearer how we use your personal data.

We use cookies to provide you with a better experience. You can read our Cookie Policy here.

Advertisement
Nuvo Announces Co-Operative Drug Development Project with Germany's Fraunhofer Institute
News

Nuvo Announces Co-Operative Drug Development Project with Germany's Fraunhofer Institute

Nuvo Announces Co-Operative Drug Development Project with Germany's Fraunhofer Institute
News

Nuvo Announces Co-Operative Drug Development Project with Germany's Fraunhofer Institute

Read time:
 

Want a FREE PDF version of This News Story?

Complete the form below and we will email you a PDF version of "Nuvo Announces Co-Operative Drug Development Project with Germany's Fraunhofer Institute"

First Name*
Last Name*
Email Address*
Country*
Company Type*
Job Function*
Would you like to receive further email communication from Technology Networks?

Technology Networks Ltd. needs the contact information you provide to us to contact you about our products and services. You may unsubscribe from these communications at any time. For information on how to unsubscribe, as well as our privacy practices and commitment to protecting your privacy, check out our Privacy Policy

Nuvo Research Inc. has announced a co-operative drug development project with the Fraunhofer Institute for Cell Therapy and Immunology IZI in Leipzig, Germany for the preclinical and clinical development of WF10 as a potential treatment for Allergic Rhinitis.

The Development Bank of Saxony in Germany (SAB) announced in late August that it will provide financial support for this co-operative project that will be conducted in Leipzig, Germany through Nuvo Research GmbH, a Nuvo subsidiary. Discussions are ongoing with SAB about expanding its financial support to include preclinical and clinical development of WF10 as a potential treatment for Rheumatoid Arthritis.

“Teaming up with exceptional partners like the Fraunhofer Institute and the Development Bank of Saxony should accelerate WF10’s preclinical and clinical development,” said Henrich Guntermann, President and Chief Executive Officer of Nuvo Research. “This partnership provides Nuvo with financial support that will allow us to more effectively deploy our own resources to develop WF10 as a needed treatment for patients who suffer from allergies and related asthma.”

The immune system provides an essential defense to micro organisms, cancer and substances it sees as foreign and potentially harmful. WF10 focuses on supporting the immune system by targeting the macrophage, a type of white blood cell that coordinates much of the immune system, to regulate normal immune function.

In conditions such as Allergic Rhinitis, the body’s immune system inappropriately responds to the presence of foreign allergens. Research suggests that in some cases, WF10 may rebalance improperly functioning immune systems.
Advertisement